PET Imaging of PARP Expression Using $^{18}$F-Olaparib

Thomas C. Wilson*1, Mary-Ann Xavier*2, James Knight2, Stefan Verhoog1, Julia Baguña Torres2, Michael Mosley2, Samantha L. Hopkins2, Sheena Wallington2, Phillip D. Allen2, Veerle Kersemans2, Rebekka Hueting2, Sean Smart2, Véronique Gouverneur1, and Bart Cornelissen2

1Department of Chemistry, University of Oxford, Oxford, United Kingdom; and 2CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom

See an invited perspective on this article on page 502.

Poly(ADP-ribose) polymerase (PARP) inhibitors are increasingly being studied as cancer drugs, as single agents, or as a part of combination therapies. Imaging of PARP using a radiolabeled inhibitor has been proposed for patient selection, outcome prediction, dose optimization, genotoxic therapy evaluation, and target engagement imaging of novel PARP-targeting agents. **Methods:** Here, via the copper-mediated $^{18}$F-radiofluorination of aryboronic esters, we accessed, for the first time, $^{18}$F-radiolabeled isotopolog of the Food and Drug Administration-approved PARP inhibitor olaparib. The use of the $^{18}$F-labeled equivalent of olaparib allows direct prediction of the distribution of olaparib, given its exact structural likeness to the native, nonradiolabeled drug. **Results:** $^{18}$F-Olaparib was taken up selectively in vitro in PARP-1-expressing cells. Irradiation increased PARP-1 expression and $^{18}$F-Olaparib uptake in a radiation-dose-dependent fashion. PET imaging in mice showed specific uptake of $^{18}$F-Olaparib in tumors expressing PARP-1 (3.2% ± 0.36% of the injected dose per gram of tissue in PSN-1 xenografts), correlating linearly with PARP-1 expression. Two hours after irradiation of the tumor (10 Gy), uptake of $^{18}$F-Olaparib increased by 70% ($P = 0.025$). **Conclusion:** Taken together, we show that $^{18}$F-Olaparib has great potential for noninvasive tumor imaging and monitoring of radiation damage. **Key Words:** PET; olaparib; PARP; cancer; molecular imaging

J Nucl Med 2019; 60:504–510

DOI: 10.2967/jnumed.118.213223

Genomic instability in tumor tissue results from oncogenic and replicative stress, exogenous genotoxic insults, and tumorspecific DNA repair defects (1). Manipulating this genomic instability provides numerous therapeutic opportunities, and inhibitors of DNA damage repair enzymes have been explored as anticancer drugs (2). These include inhibitors of poly(ADP-ribose) polymerase (PARP). PARP enzymes are part of a 17-member subfamily of enzymes with similar function. PARP-1–PARP-3 sense DNA damage by binding to nicked DNA via their zinc-finger domains and play important roles in base excision repair, with PARP-1 being the most studied. PARP inhibitors reduce the enzymes’ catalytic activity (formation of poly-ADP-ribose chains from nicotinamide adenine dinucleotide) by binding to their nicotinamide adenine dinucleotide binding pocket and interfere with the ability of the PARP-enzyme-inhibitor complex to dissociate from damaged DNA (3,4). PARP inhibitors have been extensively studied as single agents and as radiation sensitizers and are especially effective in tumors with BRCA mutations (5). Radiation sensitization using PARP inhibition is known to act via several mechanisms, including straightforward inhibition of DNA repair and synthetic lethality. Further mechanisms include inhibition of chromatin remodeling, vasodilatory effects, decreased hypoxia, contextual lethality in hypoxic cells, replication-dependent radiation sensitization, G2/M arrest leading to time cooperation (6), and a possible role for reduction of Treg cells (7). The first clinically approved and most studied PARP inhibitor is olaparib (Ku-0059436, AZ2281, Lynparza [AstraZeneca]). It inhibits the catalytic activity of PARP isoforms 1 and 2, and, albeit to a lesser extent, PARP-3. At present, over 100 clinical trials are ongoing using olaparib as a single drug or in combination with chemotherapy, immunotherapy, or radiation therapies. Other PARP inhibitors in clinical use or clinical trial include the recently approved rucaparib (Clovis Oncology), niraparib (Tesaro Inc.), talazoparib (Pfizer), as well as veliparib (AbbVie Inc.) (8).

Resistance to PARP inhibition, however, is common. It has been reported that 30%–70% of patients with mutations in DNA damage repair machinery do not respond to therapies including PARP inhibitors (9). Apart from some molecular mechanisms (10), resistance is often due to low PARP enzyme expression or to the inability of the drug to penetrate tumor tissue or part of the tumor tissue, because of increased interstitial pressure and desmoplasia—especially relevant in pancreatic adenocarcinomas—or an intact blood–brain barrier, in the case of brain tumors or brain metastases. Increased expression of drug efflux pumps may also prevent drug uptake in the tumor, most relevant for gastrointestinal and pancreatic tumors (11).

Recently, several reports have suggested that accurately measuring and monitoring PARP expression in vivo provides critical information on disease prognosis (12), as PARP expression has been found to independently correlate with worse outcomes in breast, ovarian, and other tumors (13,14). Assessment of DNA damage repair signaling activation may also contribute to genotoxic treatment evaluation, after chemo- or radiotherapy. To date, PARP expression and BRCA-ness status in tumors can be determined by immunohistochemistry or genetic sequencing on biopsy samples. However, many tumors are known to be extremely
heterogeneous—because of their increased genomic instability—but this heterogeneity is overlooked when sampling tissue from a single biopsy site. Furthermore, acquisition of reliable and high-quality biopsies is a significantly invasive and nontrivial procedure in many disease sites, such as lung, brain, or pancreas.

Given these challenges, scientists have sought to use alternative methods to measure PARP expression in vivo, especially PARP-1. Of those molecular imaging techniques available, PET has been shown to be ideal. PET allows for noninvasive, whole-body, repeatable visualization of olaparib delivery and its binding to PARP-1 to PARP-3 (15). In recent years, molecules structurally related to olaparib labeled with positron-emitting radionuclides such as 18F or 123I have been investigated for this purpose (15,16). In 2011, Reiner et al., via an inverse electron demand Diels-Alder reaction, reported access to 18F-BO, a molecule that binds PARP yet deviates significantly from the parent molecule (Fig. 1, compound 2) (17). Subsequently, a range of fluorescently and radiolabeled derivatives has been reported, of which both PARP-FL and 18F-PARPi have been used to successfully measure uptake and distribution of PARP isoforms in vivo or to perform molecular radionuclide therapy (Fig. 1) (16,18–21).

Alternatively, several radiolabeled compounds based on analogs of the PARP inhibitor rucaparib have been developed. Radioiodinated (123I, 125I), 211At-labeled, and 18F-labeled versions have been described (18,19,22,23). One of these compounds, 18F-fluorothanatrace, has been evaluated clinically, demonstrating good correlation between PARP-1 expression and 18F-fluorothanatrace uptake (24). In 2015, Andersen et al. reported an intricate 3-component carbonylation of aryl palladium species with the positron-emitting isotope 11C in the form of 11C-carbon monoxide (25). This gave the first direct, radiolabeled analog of olaparib, 14C-olaparib (Fig. 1, compound 7). The unstable nature of the palladium precursor, however, detracts from what is otherwise an elegant reaction. Moreover, 14F labeling would allow for a longer shelf life and results in intrinsically better spatial resolution.

Gouverneur’s group has developed a wide range of novel radiofluorination reactions, enabling radiolabeling of otherwise challenging motifs (26–28). Most significantly, a copper-mediated aromatic nucleophilic 18F-fluorination of aryl pinacol–derived boronic esters has enabled access to radioligands difficult to obtain applying alternative methodologies. Indeed, this method facilitated access to an isotopolog, 18F-labeled olaparib itself, from an appropriately protected, bench-stable, aryl boronic ester precursor (Fig. 2). Here, we demonstrate that, using 18F-olaparib, measurement of the distribution, uptake, and PARP binding of olaparib with PET imaging in mouse models of pancreatic ductal adenocarcinoma could be achieved. Furthermore, we report the use of 18F-olaparib for detecting DNA damage response after external-beam irradiation and its relationship with tumor hypoxia. To the best of our knowledge, this work represents the first radiosynthesis of 18F-olaparib and its in vivo translation for PET imaging.

MATERIALS AND METHODS

Full materials and methods are presented in the supplemental material accompanying this article (supplemental materials are available at http://jnm.snmjournals.org) (29–40).

Synthesis

18F-olaparib was obtained via the copper-mediated 18F-fluorodeboronation of the corresponding boronic ester precursor (Fig. 2), using methodology previously described by Tredwell et al. (26).

In Vitro Methods

PARP-1 levels were determined in a limited selection of cell lines (PSN-1, MiaPaCa-2, and CAPAN-1) using Western blot and confirmed by immunofluorescence microscopy (the supplemental material provides full details). STR profiling was used to authenticate all cell lines. CAPAN-1 cells used in this study did not match the American Type Cell Collection–held profile. However, low PARP enzyme expression was confirmed by Western blot and immunohistochemistry. Uptake of 18F-olaparib in cells was determined by exposing aliquots of cells growing in 24-well plates to external-beam radiation (0–10 Gy; using a 137Cs irradiator [0.8 Gy/min]), letting

FIGURE 1. Reported olaparib-based radiolabeled PARP imaging and radionuclide therapy agents.
the specificity of tumor uptake (0.5 mg). EF5, a hypoxia-selective marker, was injected in some of the animals, 2 h before culling. The amount of $^{18}$F uptake in selected tissue was determined and reported as a percentage of the injected dose per gram of tissue (%ID/g). Digital autoradiography was performed on tumor sections. The PET images were analyzed using PMOD (the supplemental material provides full details).

All statistical analyses and nonlinear regression were performed using GraphPad Prism (GraphPad Software). Data were tested for normality and analyzed by 1-way ANOVA, with Dunnet posttests to calculate the significance of differences between groups for multiple comparisons. All data were obtained at least in triplicate, and results are reported as mean ± SD unless indicated otherwise.

**RESULTS**

**$^{18}$F-Olaparib Synthesis via Copper-Mediated $^{18}$F-Fluorodeboronation of Aryl Pinacol Boronic Esters**

$^{18}$F-olaparib was prepared via copper-mediated $^{18}$F-fluorodeboronation of a protected boronic pinacol ester precursor (Fig. 2; Supplemental Fig. 1) in an activity yield of 18% ± 3% (nondecay-corrected radiochemical yield, $n = 5$, synthesis time of 135 min) with molar activities of up to 25.7 GBq/μmol (26). In the case of $^{18}$F-olaparib, additive preliminary screening experiments suggested that an unprotected boronic ester would be incompatible with the $^{18}$F-fluorodeboronation (Supplemental Figs. 1 and 2), potentially because of interference of the phthalazone nitrogen with the copper-complex catalyst (41). Protected boronic ester substrates bearing $N$-methyl or $N$-[2-(trimethylsilyl)ethoxy]methyl protection, respectively, underwent successful $^{18}$F-fluorodeboronation, as predicted by screening experiments (Supplemental Figs. 3–5). The optimal catalyst for $^{18}$F-fluorodeboronation of this substrate, of those tested, was shown to be Cu(OTf)$_2$(impy)$_4$ (impy = imidazo[1,2-b]pyridazine), whereas the use of 1,3-dimethyl-2-imidazolidinone proved to be the solvent that led to the optimal radiochemical yield (Supplemental Figs. 4–7; Supplemental Table 1). Crucially, an unwanted side product due to proto-deboronation of the precursor could be separated from the desired product (Supplemental Fig. 5; Supplemental Table 2), thus allowing for isolation of the pure labeled product (Supplemental Figs. 6 and 7; Supplemental Table 3).

**$^{18}$F-Olaparib Is Taken Up in PARP-1–Expressing Cell Lines In Vitro**

To demonstrate PARP targeting, a set of pancreatic ductal adenocarcinoma cell lines with varying PARP-1 expression was exposed to $^{18}$F-olaparib in vitro. $^{18}$F-olaparib was taken up within 30 min by PSN-1 cells, showing the highest uptake (Fig. 3). Results at 60 min after initial exposure of the cells to $^{18}$F-olaparib were similar. These results agreed with the relative PARP-1 expression levels in these cells as observed by Western blot (Fig. 3B) and immunocytochemistry.
**18F-Olaparib Shows Hepatobiliary Clearance in Naïve Mice**

Biodistribution and kinetics of 18F-olaparib were explored in wild-type, tumor-naïve animals. In vivo dynamic PET imaging of wild-type naïve CBA mice revealed fast pharmacokinetics and a hepatobiliary clearance pattern, after intravenous administration of 3 MBq of 18F-olaparib (Fig. 4A). On the basis of volume-of-interest analysis of 18F signal originating from a region drawn around the heart, the blood clearance of 18F-olaparib followed a bi-phasic pattern (Supplemental Fig. 10), with fast and slow half-lives of 2.8 min (44%; 95%CI, 2.1–4.0 min) and 32.3 min (56%; 95%CI, 27.6–39.1 min), respectively, resulting in a weighted half-life of 19.3 min. Given the very small injected dose of compound (0.0065 mg/kg), the blood half-life of 18F-olaparib was markedly shorter than the previously reported half-life of 58 min (in female mice) after intravenous administration of a 20 mg/kg bolus of olaparib but slower than the 5.5 min for an 18F-labeled olaparib-based PARP inhibitor reported by Carney et al. (42). Removal of selected tissues after imaging and measurement of their 18F content confirmed the results obtained through image-based quantification (Fig. 4B), showing low blood retention and high intestinal uptake of 18F-olaparib at 1 h after injection.

**18F-Olaparib Is Taken Up in PARP-1-Expressing Xenografts In Vivo**

To study PARP targeting in tumor tissue, subcutaneous tumor-bearing mice were injected intravenously with 18F-olaparib. The biodistribution and clearance pattern in xenograft-bearing animals was similar to that in naïve wild-type mice (Fig. 5). Uptake in tissues expressing PARP-1, -2, and -3 such as the spleen, bone, and pancreas was observed, and this uptake could be blocked by coinjection of an excess of cold, unlabeled olaparib, demonstrating the specificity of PARP targeting. Uptake of 18F-olaparib in PARP-1-expressing PSN-1 xenografts amounted to 3.16 ± 0.36 %ID/g, measured by biodistribution experiments at 1 h after intravenous bolus injection. This uptake correlated with PARP-1 expression measured by Western blot and immunohistochemistry (Supplemental Figs. 11 and 12). The specificity of this uptake was demonstrated by a significant decrease in tumor uptake after coinjection of an excess of cold, unlabeled olaparib, with uptake dropping to 1.20 ± 0.17 %ID/g (P = 0.0016). Coronal and transverse sections through the tumor are shown in Supplemental Figure 13. Full details on the ex vivo biodistribution results are presented in Supplemental Tables 4–7.

In contrast to PSN-1 tumors, Capan-1 xenografts expressed lower levels of PARP-1, as determined by Western blot and immunohistochemistry (Fig. 5D; Supplemental Figs. 11–13). Consistent with lower

---

**FIGURE 4.** (A) Representative dynamic PET images after intravenous bolus injection of 18F-olaparib (3 MBq). Middle of time frames is indicated in minutes. Images are presented as maximum-intensity projections. (B) Biodistribution in wild-type CBA mice at 1 h after injection of 18F-olaparib. C = cecum; G = gallbladder; I = small intestine; L = liver.

**FIGURE 5.** (A) Schematic of experimental design of imaging experiments. Mice were irradiated or sham-irradiated 2 h before injection of 18F-olaparib. (B) Biodistribution in mice bearing PSN-1 xenografts 1 h after injection of 18F-olaparib (3 MBq). (C) Representative coronal and transverse images of PSN-1 xenograft-bearing mice 1 h after injection of 18F-olaparib. Dashed lines indicate position of xenograft tumor. Insets represent autoradiograms of tumor sections, corroborating PET imaging results. (D) Western blot shows increased PARP-1 levels in 3 irradiated compared with 3 nonirradiated PSN-1 xenografts.
tumor PARP-1 levels, and consistent with lower in vitro uptake of 18F-olaparib, intravenous administration resulted in lower average uptake of 18F-olaparib in these tumors (2.59 ± 0.32 %ID/g), although this was not statistically significant. Uptake in Capan-1 xenografts could be blocked (to 1.00 ± 0.17; P = 0.015), indicating specific uptake of the tracer. CaNT tumors, also expressing low amounts of murine PARP-1 (Supplemental Figs. 14 and 15) had specific uptake of the tracer. CaNT tumors, also expressing low cells after 6 hours, although immunofluorescence microscopy suggested some expression of PARP-1 (Supplemental Fig. 8). In line with these results, 18F-olaparib uptake was increased in all cells after 6 hours, in a radiation dose-dependent manner, which was more pronounced at later times after irradiation and in PSN-1 cells (Fig. 3D).

In vivo, 2 h after irradiation of PSN-1 xenografts (10 Gy), uptake of 18F-olaparib in the tumor tissue was increased by 70%, from 3.16 ± 0.36 to 5.35 ± 1.16 %ID/g (P = 0.025) (Fig. 5). This result was consistent with earlier data reported by Kossatz et al. (43), who used a fluorescently labeled version of olaparib, visualized using in vivo optical fluorescence imaging or ex vivo confocal microscopy. The increased expression of PARP-1 in PSN-1 xenografts was confirmed ex vivo using Western blot (Fig. 5D; Supplemental Fig. 11).

**Relationship Between Hypoxia and PARP-1 Expression**

It is well known that genomic stability in tumor tissue is greatly reduced in hypoxic regions (44). To investigate the relationship between hypoxia and PARP-1 expression in vivo in tumor xenografts, we compared PARP-1 signal intensity with EF5 staining, which is known to accumulate in regions of clinically relevant hypoxia. A clear correlation between PARP-1 staining and EF5 uptake could be observed in all samples (a representative example is shown in Supplemental Fig. 17), both irradiated and nonirradiated. This observation, in combination with the increased delivery of 18F-olaparib to tumors with increased PARP-1 content, suggests that olaparib and other PARP inhibitors will be more effective in hypoxic tumor tissue. This prediction is consistent with previous observations by Jiang et al., who demonstrated contextual synthetic lethality for hypoxia and PARP inhibition, with hypoxic cells and tumors being up to a third more sensitive to PARP inhibition than are fully oxygenated controls (45).

**DISCUSSION**

PARP inhibitors are being intensively studied after the elucidation of the role of PARylation enzymes in DNA damage repair, and the identification of the PARP enzyme, now known as PARP-1 (one of 17 in the PARP enzyme superfamily). Clinical trials were set up to study the effects of a wide variety of compounds, including olaparib (AZD2281, KU0059436), rucaparib (AG-014699, PF-01367338), veliparib (ABT-888), niraparib (MK-4827), talazoparib (BMN-673), and CEP-9722, all of which have been designed to compete for binding to the nicotinamide adenine dinucleotide binding pocket of the PARP enzymes. Most of these inhibitors are selective for PARP-1 and -2, with PARP-3 also being inhibited by some, although to a lesser degree. PARP inhibition is largely successful, especially when used in synthetic lethal combination settings, such as in preselected tumors with BRCA-ness signatures (46).

Nonetheless, resistance to PARP inhibitor treatment is common. Aside from some genetic mechanisms, the failure to deliver therapeutically adequate amounts of drug to the tumor tissue has been suggested as a likely cause, especially in brain and pancreatic tumors (10,11). It has been argued that this may be due to low systemic doses (e.g., as a result of poor oral availability), rapid clearance or metabolism, nonspecific sequestration by nontarget organs, rapid export by drug transporter (olaparib is known substrate of p-glycoprotein), lack of the target enzyme, or mutations in the binding pocket, reducing drug affinity (47). For all these reasons, using a radiolabeled form of the drug will reveal if drug accumulation in the tumor is therapeutically limiting. Imaging of PARP expression using radiolabeled PARP inhibitors, and imaging the delivery of a radiolabeled version of the drug, will assist in identifying those patients who will or will not respond to the treatment.

A variety of radiolabeled PARP inhibitors has been developed in recent years, all based on either olaparib-like structures (Reiner’s group (17,18,20,42,43), Zmuda et al. (48), Huang et al. (49), this study) or rucaparib-like structures (Makvandi’s group, Reilly et al. (19,23–25)). An excellent review on the subject has been previously published (16). Some radiolabeled PARP inhibitors are also being studied as radionuclide therapy agents (20). Although a direct comparison between 18F-olaparib (this work) and other radiolabeled PARP imaging agents is hampered by the different model systems that are being used, the main advantage of 18F-olaparib is its relatively high tumor uptake, a good contrast between PARP-expressing tumors and non–PARP-expressing tumors, and fast tumor uptake kinetics. One key challenge 18F-olaparib shares with all other radiolabeled PARP inhibitors is its hepatobiliary clearance pattern, making imaging in the mouse abdomen more challenging. In the clinic, this challenge could be averted by PET/CT or PET/MRI, which would make localization of lesions more straightforward, especially in ovarian and breast tumors, for which PARP inhibitors are primarily used. Being an isotopolog of the unlabeled drug olaparib, 18F-olaparib benefits from a wealth of clinical data already available, which will aid its translation to the clinic. As an exact chemical match of olaparib, 18F-olaparib allows direct imaging of the delivery of olaparib to tumor tissues and can act as a direct companion imaging biomarker for treatment prediction. The radiofluorination chemistry we have used here would allow use of a similar strategy on a much larger scale of cancer drugs, since it allows radiolabeling of a much larger group of compounds than was previously possible. The use of isotopologs for PET imaging benefits from a large set of structure–activity relationship data and extensive toxicity profiling available through the drug development process. However, it does not necessarily follow that the superior therapeutic agent also makes for a better PET imaging agent, given that an imaging agent should...
comply with a different set of criteria. The main advantage of an isotopolog is the faster route to clinical translation that may be possible, given the reduced need for toxicity data that should be presented to the regulator.

Although PARP-1 is by far the most abundant of the DNA damage repair–relevant isoforms of PARP, and a PARP-1–selective imaging agent may predict the outcome of PARP inhibition therapy better (18), 18F-olaparib is not selective for one specific isoform. It has previously been well recognized that olaparib affects PARP-1, PARP-2, and PARP-3 alike, albeit with varying effects (IC_{50} of olaparib for PARP-1 and PARP-2 is 5 and 1 nM, respectively). It is also known that replacement of the cyclopropyl side chain in olaparib with a methoxy-moiety (AZD2461 (50)) significantly reduces its affinity toward PARP-3 and consequently reduces PARP-3–mediated bone marrow toxicity in a murine model. In addition, this compound has been described to have a lower affinity for p-glycoprotein drug efflux pumps (5). Here, we did not evaluate the influence of p-glycoprotein pumps for which olaparib, and thus 18F-olaparib, is a known substrate, although one of the cell lines we used here, Capan-1, does express some, as demonstrated by Western blot on whole-cell lysates (Supplemental Fig. 18).

Thus, different versions of radiolabeled PARP inhibitors may therefore provide subtly different readouts, and care should be taken in comparing them directly. For example, none of the small-molecule inhibitors of PARP described so far uniquely bind to PARP-1 alone. The only imaging agent with this ability is a PARP-1–selective single-domain antibody–red fluorescent protein fusion protein (51). Its use, however, is limited to transfected cells in vitro, as it cannot cross the cell membrane, thus limiting the set of currently available in vivo imaging agents for PARP to radiolabeled small molecules.

The use of PARP imaging for evaluating irradiated tissue was first explored by Kossatz et al. using a fluorescently labeled version of olaparib (43). Molecular imaging of the biologic effects of radiation therapy holds great promise for precision cancer therapy and may aid in tailoring radiotherapy dose schedules to the individual tumor’s response. Previously, we explored an imaging agent targeting γH2AX for this purpose, 111In- or 90Zr-labeled anti-γH2AX-TAT (15,52–54). γH2AX is a phosphorylated histone expressed around DNA double-strand breaks and has been used extensively as a radiation damage marker. Given that this imaging agent is based on an antibody, clinical translation may be more challenging. Therefore, imaging the radiation damage response using radiolabeled PARP inhibitors may offer an alternative, since some are already being evaluated in early-phase clinical trials.

We hypothesize that, when translated to the clinic, PET imaging with radiolabeled compounds such as 18F-olaparib will allow better patient selection by determining tumor drug uptake; measurement of the biologic effects of genotoxic cancer treatment, such as chemotherapeutic and radiotherapy; and better patient stratification, making the therapeutic use of PARP inhibitors even more effective, albeit in a more stringently selected patient population. One early phase 1 clinical trial using a PARP inhibitor–based imaging agent is now published (using 18F-fluorothanatrace; www.clinicaltrials.gov), the results of which will undeniably inform the field of future directions (55).

**CONCLUSION**

Taken together, we show here that 18F-olaparib can be used for quantifying olaparib tumor accumulation in vitro and in vivo. This study serves as an expansion of the evidence base for the use of PARP imaging agents for clinical PET. The use of the 18F-labeled isotopolog of olaparib allows direct prediction of the distribution of olaparib, given its exact structural likeness to the native, non-radiolabeled drug. The translation of this diagnostic strategy to the clinic will significantly improve patient stratification as well as therapy response monitoring.

**DISCLOSURE**

This research was supported by Pancreatic Cancer U.K.; the Pancreatic Cancer Research Fund; CRUK through the Oxford Institute for Radiation Oncology, the CRUK Oxford Centre, and the CRUK/EPSCR Imaging Centre in Oxford; the EPSCR (EP/L025604/1, NS/A000024/1); and CRUK C5255/A16466. The work herein is subject to a U.K. priority patent application. This research was also supported by a Wolfson Research Merit Award from the Royal Society (Véronique Gouverneur) and a Junior Group Leader award from Cancer Research U.K. (Bart Cornelissen). No other potential conflict of interest relevant to this article was reported.

**REFERENCES**

1. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481:287–294.
2. O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60:547–560.
3. Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72:5588–5590.
4. Marchand JR, Carotti A, Passeri D, et al. Investigating the allosteric reverse signalling of PARP inhibitors with microscopic molecular dynamic simulations and fluorescence anisotropy. Biochim Biophys Acta. 2014;1844:1765–1772.
5. Lowery MA, Kelsen DP, Stadler ZK, et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist. 2011;16:1397–1402.
6. Lesueur P, Chevalier F, Austry JB, et al. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget. 2017;8:69105–69124.
7. Rosado MM, Bennici E, Novelli F, Pioti C. Beyond DNA repair, the immunological role of PARP-1 and its siblings. Immunology. 2013;139:428–437.
8. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152–1158.
9. Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015;13:188.
10. Kim Y, Kim A, Sharp A, Jiang J, Yang Q, Xie Y. Reverse the resistance to PARP inhibitors. Int J Biol Sci. 2017;13:198–208.
11. O’Driscoll L, Walsh N, Larkin A, et al. Poly-(ADP-ribose)-polymerase inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152–1158.
12. Livehag L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015;13:188.
13. Knight JC, Kossatz S, Reiner T. Molecular imaging of PARP. Eur J Nucl Med Mol Imaging. 2012;39:1922–1925.
14. Rojo F, Garcia-Parras J, Zaro S, et al. Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol. 2012;23:1156–1164.
15. Noordzij J, Koutoulidou S, Cornelissen B. Imaging the DNA damage response with PET and SPECT. Eur J Nucl Med Mol Imaging. 2017;44:1065–1078.
16. Carney B, Kossatz S, Reiner T. Molecular imaging of PARP. J Nucl Med. 2017;58:1025–1030.
17. Reiner T, Kelhier EJ, Earley S, Marinelli B, Weissleder R. Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method. Angew Chem Int Ed Engl. 2011;50:1922–1925.
18. Carlucci G, Carney B, Brand C, et al. Dual-modality optical/PET imaging of PARP1 in glioblastoma. Mol Imaging Biol. 2015;17:848–855.
19. Reilly SW, Makvandi M, Xu K, Mach RH. Rapid Cu-catalyzed [11]Atastatination and [11]Aiodination of boronic esters at room temperature. Org Lett. 2018;20:1715–1718.

20. Jannetti SA, Carlucci G, Carney B, et al. PARP-1 targeted radiotherapy in mouse models of glioblastoma. J Nucl Med. 2018;59:1225–1233.

21. Anderson RC, Makvandi M, Xu K, et al. Iodinated benzimidazolone PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo. Nucl Med Biol. 2016;43:752–758.

22. Makvandi M, Xu K, Lieberman BP, et al. A radiotracer strategy to quantify PARP-1 expression in vivo provides a biomarker that can enable patient selection for PARP inhibitor therapy. Cancer Res. 2016;76:4516–4524.

23. Sander Effron S, Makvandi M, Lin L, et al. PARP-1 expression quantified by 18F-FluorThanatrace: a biomarker of response to PARP inhibition adjuvant to radiation therapy. Cancer Biother Radiopharm. 2017;32:9–15.

24. Makvandi M, Pantel A, Schwartz L, et al. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. J Clin Invest. 2018;128:2116–2126.

25. Andersen TL, Friis SD, Audrain H, Nordeman P, Antoni G, Skyndstrup T. Efficient 11C-carbonylation of isolated aryl palladium complexes for PET: application to challenging radiopharmaceutical synthesis. J Am Chem Soc. 2015;137:1548–1555.

26. Tredwell M, Preshlock SM, Taylor NJ, et al. A general copper-mediated nucleophilic 18F-fluorination of arenes. Angew Chem Int Ed Engl. 2014;53:7751–7755.

27. Preshlock S, Calderwood S, Verhoog S, et al. Enhanced copper-mediated 18F-fluorination of aryl boronic esters provides eight radiotracers for PET applications. Chem Commun (Camb). 2016;52:8361–8364.

28. Preshlock S, Tredwell M, Gouverneur V. 18F-labeling of arenes and heteroarenes for applications in positron emission tomography. Chem Rev. 2016;116:719–766.

29. Pangborn AB, Giardello MA, Grubbs RH, Rosen RK, Timmers FJ. Safe and convenient procedure for solvent purification. Organometallics. 1996;15:1518–1520.

30. Menear KA, Addcock C, Boulter R, et al. 4-[3-(4-cyclopropene carbon)pyrrole-1-carbonyl]-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008;51:6581–6591.

31. Raval P, Borozdin Y, Ito Y, Enkelmann V, Baumgarten M. Crystal engineering of tolane bridged nitronyl nitroxide biradicals: candidates for quantum magnets. Cryst Growth Des. 2014;14:5840–5846.

32. Outerbridge VM, Landge SM, Tamaki H, Toörk B. Microwave-promoted solid-acid catalyzed one-pot synthesis of phthalazinones. Synthesis. 2009;11:1801–1806.

33. Nezhawy AOH, Gaballah ST, Radwan MAA. Studying the reactivity of (phthalazin-1(2H)-en-2-y1)methyl trichloroacetimidate towards different C- and O-nucleophiles. Tetrahedron Letters. 2009;50:6646–6650.

34. Cornelissen B, Hu M, McLarty K, Costantini D, Reilly RM. Cellular penetration and nuclear importation properties of 111In-labeled and 125I-labeled HIV-1 tat peptide immunocjugates in BT-474 human breast cancer cells. Nucl Med Biol. 2007;34:37–46.

35. Thibur JM, Reiner T, Yang KS, Kohler RH, Weisleder R. Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors. Mol Cancer Ther. 2014;13:986–995.

36. Reiner T, Lacy J, Kielher EJ, et al. Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. Neoplasia. 2012;14:169–177.

37. Kersemans V, Cornelissen B, Hueting R, et al. Hypoxia imaging using PET and SPECT: the effects of anesthetic and carrier gas on [15]Cu-ATSM. [15]Tc-HL91 and [18]F-MISO tumor hypoxia accumulation. PLoS One. 2011;6:e25911.

38. EF5 procedure manual. Hypoxia-Imaging.org website. http://www.hypoxia-imaging.org/v2/methods/e5manual.htm. Accessed November 5, 2018.

39. Lee J, Steimann DW, Koch CJ, Lord EM. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. Int J Cancer. 1996;67:372–378.

40. Hueting R, Kersemans V, Cornelissen B, et al. A comparison of the behavior of 64Cu-acetate and 64Cu-ATSM in vitro and in vivo. J Nucl Med. 2014;55:128–134.

41. Taylor NJ, Emer E, Preshlock S, et al. Derisking the Cu-mediated 18F-fluorination of heterocyclic positron emission tomography radioligands. J Am Chem Soc. 2017;139:8267–8276.

42. Carney B, Carlucci G, Salinas B, et al. Non-invasive PET imaging of PARP expression in glioblastoma models. Mol Imaging Biol. 2016;18:386–392.

43. Kossatz S, Weber WA, Reiner T. Optical imaging of PARP1 in response to radiation in oral squamous cell carcinoma. PLoS One. 2016;11:e0147752.

44. Bristow RG, Hill RP. Hypoxia and metabolism: hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008;8:180–192.

45. Jiang Y, Verbiest T, Devery AM, et al. Hypoxia potentiates the radiation-sensitizing effect of olaparib in human non-small cell lung cancer xenografts by contextual synthetic lethality. Int J Radiat Oncol Biol Phys. 2016;95:772–781.

46. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8:193–204.

47. Thibur JM, Yang KS, Reiner T, et al. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat Commun. 2013;4:1504.

48. Zmuda F, Malviya G, Blair A, et al. Synthesis and evaluation of a radioidinated tracer with specificity for poly(ADP-ribose) polymerase-1 (PARP-1) in vivo. J Med Chem. 2015;58:8683–8693.

49. Huang T, Hu P, Bantizs AB, He J. Initial evaluation of Cu-64 labeled PARP-DOTA PET imaging in mice with mesothelioma. Bioorg Med Chem Lett. 2017;27:3472–3476.

50. Oplustil O’Connor L, Rulten SL, Cranston AN, et al. The PARP inhibitor AZD2461 provides insights into the role of PARP3 inhibition for both synthetic lethality and tolerability with chemotherapy in preclinical models. Cancer Res. 2016;76:6084–6094.

51. Buchfellner A, Yurlova L, Naske S, et al. A new nanobody-based biosensor to study endogenous PARP1 in vitro and in live human cells. PLoS One. 2016;11:e0151041.

52. Knight JC, Mosley MJ, Bravo LC, et al. [9Z]-anti-gammaH2AX-TAT but not 18F-FDG allows early monitoring of response to chemotherapy in a mouse model of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2017;23:6498–6504.

53. Knight JC, Topping C, Mosley M, et al. PET imaging of DNA damage using 18F-fluorinated anti-gammaH2AX-TAT immunocjugates. Eur J Nucl Med Mol Imaging. 2015;42:1707–1717.

54. Cornelissen B, Kersemans V, Darbar S, et al. Imaging DNA damage in vivo using gammaH2AX-targeted immunocjugates. Cancer Res. 2011;71:4539–4549.

55. Makvandi M, Pantel A, Schwartz L, et al. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. J Clin Invest. 2018;128:2116–2126.
PET Imaging of PARP Expression Using $^{18}$F-Olaparib

Thomas C. Wilson, Mary-Ann Xavier, James Knight, Stefan Verhoog, Julia Baguña Torres, Michael Mosley, Samantha L. Hopkins, Sheena Wallington, Phillip D. Allen, Veerle Kersemans, Rebekka Hueting, Sean Smart, Véronique Gouverneur and Bart Cornelissen

*J Nucl Med.* 2019;60:504-510.
Published online: November 2, 2018.
Doi: 10.2967/jnumed.118.213223

This article and updated information are available at: http://jnm.snmjournals.org/content/60/4/504

Information about reproducing figures, tables, or other portions of this article can be found online at: http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at: http://jnm.snmjournals.org/site/subscriptions/online.xhtml